Outcomes With Aflibercept 8 mg and 2 mg by Prior DME Treatment Status: A Subgroup Analysis of the Phase 2/3 PHOTON Trial

Sunir J Garg MD FACS FASRS,[1,2] on behalf of the PHOTON study investigators

[1]Mid Atlantic Retina, The Retina Service of Wills Eye Hospital;
[2]Thomas Jefferson University, Philadelphia, Pennsylvania

Presented at the American Academy of Ophthalmology (AAO) Annual Meeting, October 18–21, 2024

Disclosures

- Dr. Garg served as a consultant for the American Academy of Ophthalmology, Apellis, Bausch & Lomb, Boehringer Ingelheim, Merck Manual, and West Pharmaceuticals; received research funding from the American Academy of Ophthalmology, Apellis, Boehringer Ingelheim, Genentech, NGM Bio, Regeneron Pharmaceuticals, Inc., and Kodiak Bioscience; served on an advisory board for Coherus; and has received lecture fees from the Canadian Ophthalmological Society, Cole Eye Summit, Physicians' Education Resource, and Retina Fellows Forum
- The PHOTON study was sponsored by Regeneron Pharmaceuticals, Inc. (Tarrytown, New York) and co-funded by Bayer AG (Leverkusen, Germany). This analysis was funded by Regeneron Pharmaceuticals, Inc. (Tarrytown, NY). The sponsors participated in the design and conduct of this analysis, data interpretation, and preparation of this presentation
- Study disclosures: This study includes research conducted on human patients. Institutional review board approval was obtained prior to study initiation
- Medical writing support was provided by Abbie Rodger, BSc, of Core (a division of Prime, London, UK), funded by Regeneron Pharmaceuticals, Inc. according to Good Publication Practice guidelines

Background

- Aflibercept 8 mg is a novel intravitreal formulation that delivers a 4-times higher molar dose than aflibercept 2 mg, potentially extending VEGF suppression over a longer period
- In the PHOTON trial, aflibercept 8 mg demonstrated non-inferior BCVA gains with extended dosing intervals versus aflibercept 2 mg in patients with DME, with no new safety signals through Week 96[1]
  - Given that approximately 44% of patients in PHOTON received prior treatment for DME,[a] there is an opportunity to assess treatment outcomes in patients with prior DME treatment

This subgroup analysis of the PHOTON trial evaluated visual and anatomic outcomes in patients by prior DME treatment status

[a]Previous treatments for DME were laser, intravitreal anti-VEGF therapy, and corticosteroids.
BCVA, best-corrected visual acuity; DME, diabetic macular edema; VEGF, vascular endothelial growth factor.
1. Do DV. Presented at: American Academy of Ophthalmology; November 3-6, 2023; San Francisco, CA.

PHOTON Study Design

Multi-center, randomized, double-masked study in adult patients with center-involved DME[a]
Randomized 1 (2q8) : 2 (8q12) : 1 (8q16)
Note: 2 mg arm received 5 initial monthly injections versus 8 mg arms, which received only 3 initial monthly injections

2q8
Aflibercept 2 mg every 8 weeks after 5 initial monthly injections
n=167

8q12
8 mg every 12 weeks after 3 initial monthly injections
n=328

8q16
8 mg every 16 weeks after 3 initial monthly injections
n=163

Primary endpoint at Week 48
Mean change in BCVA (non-inferiority)

↓

End of study at Week 96
with optional 1-year extension through Week 156

[a]Treatment-naive and previously treated patients aged ≥18 years with type 1 or type 2 diabetes, DME with central involvement with CRT ≥300 µm in the study eye, and BCVA of 78-24 letters (Snellen equivalent of 20/32-20/320) with decreased vision due to DME.
2q8, 2 mg every 8 weeks; 8q12, 8 mg every 12 weeks; 8q16, 8 mg every 16 weeks; CRT, central retinal thickness.

PHOTON: Dosing Schedule and Dose Regimen Modification

Primary Endpoint

Year 1	Day 1	Week 4	Week 8	Week 12	Week 16	Week 20	Week 24	Week 28	Week 32	Week 36	Week 40	Week 44	Week 48
2q8	X	X	X	X	X	o	X	o	X	o	X	o	X
8q12	X	X	X	o	o[a]	X[a]	o	o	X[a]	o	o	X[a]	o
8q16	X	X	X	o	o[a]	o[a]	X[a]	o	o	o	X[a]	o	o

Year 2	Week 52	Week 56	Week 60	Week 64	Week 68	Week 72	Week 76	Week 80	Week 84	Week 88	Week 92	Week 96
2q8	o	X	o	X	o	X	o	X	o	X	o	
8q12	o	X[a,b]	o	o	X[a,b]	o	o	X[a,b]	o	o	X[a,b]	
8q16	o	X[a,b]	o	o	o	X[a,b]	o	o	o	X[a,b]	o	

[a]DRM: Interval Shortening During Years 1 and 2

- **Criteria for interval shortening:**
  - >10-letter loss in BCVA from Week 12 due to persistent or worsening DME **AND**
  - >50-µm increase in CRT from Week 12
- Patients who met DRM criteria had dosing intervals shortened to Q8 at **Weeks 16** and **20** or by 4-week increments from **Week 24**
  - The minimum interval was Q8

[b]DRM: Interval Extension During Year 2

- **Criteria for interval extension:**
  - <5-letter loss in BCVA from Week 12 **AND**
  - CRT <300 µm (or <320 µm on Spectralis)
- Patients who met DRM criteria beginning at **Week 52** had dosing intervals extended by 4-week increments
  - The maximum assigned interval was Q24

Figure does not reflect all dosing options once a patient's interval is shortened or extended. Stippled boxes = initial treatment phase; **X** = active injection; o = sham injection.
DRM, dose regimen modification; Q8, every 8 weeks; Q24, every 24 weeks.

Baseline Demographics

	With Prior DME Treatment			Without Prior DME Treatment		
	2q8 (n=74)	8q12 (n=146)	8q16 (n=71)	2q8 (n=93)	8q12 (n=182)	8q16 (n=92)
Age, years	64.4 (8.9)	62.7 (10.9)	63.0 (8.4)	62.0 (10.4)	61.6 (11.3)	60.9 (10.3)
Female, %	45.9	39.7	40.8	44.1	33.0	38.0
Race, %						
White	64.9	69.2	77.5	68.8	71.4	79.3
Asian	21.6	19.9	18.3	15.1	10.4	10.9
Black or African American	9.5	7.5	4.2	11.8	13.2	6.5
American Indian or Alaskan Native	0.0	0.7	0.0	0.0	0.5	0.0
Other	2.7	1.4	0.0	2.2	2.2	1.1
Not reported	1.4	1.4	0.0	2.2	1.1	2.2
Hispanic or Latino, %	18.9	17.1	22.5	18.3	15.9	19.6
Duration of diabetes, years	16.7 (10.6)	16.2 (9.4)	16.6 (9.7)	15.5 (9.6)	14.5 (10.3)	15.0 (11.4)

Data are mean (SD) unless otherwise indicated.
SD, standard deviation.

Baseline Ocular Characteristics

	With Prior DME Treatment			Without Prior DME Treatment		
	2q8 (n=74)	8q12 (n=146)	8q16 (n=71)	2q8 (n=93)	8q12 (n=182)	8q16 (n=92)
BCVA, ETDRS letters	62.1 (10.9)	62.2 (10.7)	58.6 (11.9)	61.0 (11.5)	64.8 (9.5)	63.7 (11.2)
Snellen equivalent, %						
20/32 (>73 to 78 letters)	14.9	16.4	5.6	9.7	19.2	20.7
20/40 or worse (≤73 letters)	85.1	83.6	94.4	90.3	80.8	79.3
CRT, µm	472.7 (162.3)	456.9 (123.9)	460.6 (109.3)	444.9 (127.1)	442.9 (130.2)	460.1 (124.7)
DRSS categories, %						
Better or equal to level 43	70.3	66.4	67.6	57.0	54.9	64.1
Level 47 or worse	25.7	28.1	23.9	36.6	39.6	31.5
Missing/ungradable	4.1	5.5	8.5	6.5	5.5	4.3

Data are mean (SD) unless otherwise indicated.
ETDRS, Early Treatment Diabetic Retinopathy Study.

Mean Change in BCVA Through Week 96

With Prior DME Treatment



Without Prior DME Treatment



FAS, observed cases.
FAS, full analysis set.

Mean Change in CRT Through Week 96

With Prior DME Treatment



Without Prior DME Treatment



FAS, observed cases.

Proportion of Patients With ≥2-Step DRSS Improvement From Baseline at Week 96

With Prior DME Treatment



Without Prior DME Treatment



FAS, LOCF.
LOCF, last observation carried forward.

Proportion of Patients With Baseline DRSS 47 or Worse and ≥2-Step DRSS Improvement from Baseline at Week 96

With Prior DME Treatment



Without Prior DME Treatment



FAS, LOCF.

Large Proportion of Patients Qualified for Interval Extension in Year 2[a]





Values may not add up to 100% due to rounding.

[a]Dosing intervals were extended in Year 2 if patients had <5-letter loss in BCVA from Week 12 and CRT <300 µm (or <320 µm on Spectralis). [b]Patients were assigned to 24-week dosing intervals if they continued to meet extension criteria but there was not sufficient time to complete the interval within the 96-week study period. [c]Patients completing Week 96.

BL, baseline; Q8, every 8 weeks; Q12, every 12 weeks; Q16, every 16 weeks; Q20, every 20 weeks; Q24, every 24 weeks.

Conclusions







- BCVA gains and proportions of patients with ≥2-step improvement in DRSS score at Week 96 trended numerically higher across all treatment groups in patients without versus with prior DME treatment
- In patients with prior DME treatment, mean BCVA gain from baseline to Week 96 was greater with 2q8 and 8q12 compared with 8q16 suggesting that some patients could have benefited from more frequent treatment in this subgroup
- Similar proportions of patients in the 8q12 and 8q16 groups had a last assigned dosing interval of at least 20 weeks at Week 96 irrespective of prior DME treatment status